Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe

被引：16
|
作者：
Schlander, Michael [1 ,2 ]
Adarkwah, Charles Christian [3 ]
Gandjour, Afschin [4 ]
机构：
[1] Inst Innovat & Valuat Hlth Care InnoValHC, D-65197 Wiesbaden, Germany
[2] Heidelberg Univ, Dept Publ Hlth Social & Prevent Med, Mannheim Med Fac, Mannheim, Germany
[3] Univ Marburg, Dept Gen Practice, Marburg, Germany
[4] Frankfurt Sch Finance & Management, Frankfurt, Germany
来源：
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2015年 / 15卷 / 01期
关键词：
budget impact analysis; drugs; Europe; non-oncological diseases; ultra-orphan; RARE; PRINCIPLES;
D O I：
10.1586/14737167.2015.965156
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Background/aim: Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. Methods: For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European payer's perspective, based on prevalence data for UODs for which patented drugs are available and/or for which drugs are in clinical development. Results: A total of 18 drugs under patent protection or orphan drug designation for non-oncological UODs were identified. Furthermore, 29 ultra-orphan drugs for non-oncological diseases under development that have the potential of reaching the market by 2021 were found. Total budget impact over 10 years was estimated to be (sic)15,660 and (sic)4965 million for approved and pipeline ultra-orphan drugs, respectively (total: (sic)20,625 million). Conclusion: The analysis does not support concerns regarding an uncontrolled growth in expenditures for drugs for UODs.
引用
收藏
页码：171 / 179
页数：9
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF DRUGS FOR ULTRA-RARE NON-ONCOLOGICAL DISEASES IN EUROPE
    Schlander, M.
    Gandjour, A.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A525 - A525
  • [2] MARKET ACCESS AND PRICING ANALYSIS OF ULTRA-ORPHAN DRUGS
    Malacan, J.
    Gabriel, S.
    Dinet, J.
    Forget, S.
    Borget, I
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
  • [3] The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review
    Schuller, Y.
    Hollak, C. E. M.
    Biegstraaten, M.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [4] The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
    Y. Schuller
    C. E. M. Hollak
    M. Biegstraaten
    [J]. Orphanet Journal of Rare Diseases, 10
  • [5] ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND
    Achour, L.
    Hanna, E.
    Borrisov, B.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S446 - S446
  • [6] TITLE: ACCESS TO ORPHAN AND ULTRA-ORPHAN DRUGS IN CHINA
    Gambari, J.
    Yang, M.
    Chowdhury, C. A.
    Duttagupta, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A826 - A826
  • [7] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [8] Fertility protection in oncological and non-oncological diseases
    von Wolff, Michael
    Nawroth, Frank
    [J]. GYNAKOLOGISCHE ENDOKRINOLOGIE, 2020, 18 (03): : 155 - 168
  • [9] Budget-impact of drugs for orphan diseases (orphan drugs) in the Israeli health basket: a longitudinal analysis
    Morginstin, Tal
    Hammerman, Ariel
    Triki, Noa
    Weinreb, Baruch
    [J]. ISRAEL JOURNAL OF HEALTH POLICY RESEARCH, 2019, 8 (01):
  • [10] PATIENT VOICE IN SMC TECHNOLOGY APPRAISALS FOR ORPHAN AND ULTRA-ORPHAN DISEASES
    Gupta, A.
    Jindal, S.
    Mahajan, K.
    Sharma, A.
    Saharia, P.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S486 - S486
12345